Becton, Dickinson and Company (NYSE:BDX ) Goldman Sachs 46th Annual Global Healthcare Conference June 9, 2025 2:00 PM ET Company Participants Thomas E. Polen - President, CEO & Chairman Conference Call Participants Robert Justin Marcus - JPMorgan Chase & Co, Research Division Unidentified Analyst Yes.
Becton, Dickinson is significantly undervalued, trading at 12.3x earnings with a 2.5% dividend yield, the highest in a decade. The company boasts a 53-year streak of dividend growth, excellent dividend safety, and a conservative payout ratio, making it a reliable Dividend King. Despite tariff headwinds, competition, and restructuring risks, BDX's innovation, acquisitions, and organic growth support long-term revenue and EPS expansion.
BDX warns of safety risks tied to its esophagogastric balloon tamponade tubes after one death and two injuries, prompting updated usage instructions for clinicians.
![]() BDX 1 weeks ago Announced | Quarterly | $1.04 Per Share |
![]() BDX 3 months ago Paid | Quarterly | $1.04 Per Share |
![]() BDX 6 months ago Paid | Quarterly | $1.04 Per Share |
![]() BDX 9 months ago Paid | Quarterly | $0.95 Per Share |
![]() BDX 10 Jun 2024 Paid | Quarterly | $0.95 Per Share |
7 Aug 2025 (50 Days) Date | | - Cons. EPS | - EPS |
31 Jul 2025 (43 Days) Date | | - Cons. EPS | - EPS |
1 May 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | 2.99 Cons. EPS | 3.43 EPS |
7 Nov 2024 Date | | 3.77 Cons. EPS | 3.81 EPS |
![]() BDX 1 weeks ago Announced | Quarterly | $1.04 Per Share |
![]() BDX 3 months ago Paid | Quarterly | $1.04 Per Share |
![]() BDX 6 months ago Paid | Quarterly | $1.04 Per Share |
![]() BDX 9 months ago Paid | Quarterly | $0.95 Per Share |
![]() BDX 10 Jun 2024 Paid | Quarterly | $0.95 Per Share |
7 Aug 2025 (50 Days) Date | | - Cons. EPS | - EPS |
31 Jul 2025 (43 Days) Date | | - Cons. EPS | - EPS |
1 May 2025 Date | | - Cons. EPS | - EPS |
30 Jan 2025 Date | | 2.99 Cons. EPS | 3.43 EPS |
7 Nov 2024 Date | | 3.77 Cons. EPS | 3.81 EPS |
Medical - Instruments & Supplies Industry | Healthcare Sector | Mr. Thomas E. Polen Jr. CEO | CXA Exchange | US0758871091 ISIN |
US Country | 70,000 Employees | 10 Mar 2025 Last Dividend | 1 Apr 2022 Last Split | - IPO Date |
Becton, Dickinson and Company, commonly known as BD, is a global leader in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. Catering to healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry, and the general public, BD operates worldwide. The company’s extensive product portfolio is strategically segmented into three core areas: BD Medical, BD Life Sciences, and BD Interventional. Founded in 1897, BD has established a robust presence in the healthcare sector, headquartered in Franklin Lakes, New Jersey.
This segment provides a comprehensive range of products, including peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, and vascular access technology. It also offers vascular care, preparation products, needle-free IV connectors, closed-system drug transfer devices, hazardous drug detections, and a variety of syringes and needles. For drug delivery and safety, it covers IV medication safety and infusion therapy delivery systems, medication compounding workflow systems, as well as automated medication dispensing and supply management systems, enhancing medication inventory optimization and tracking. Additionally, BD Medical produces prefillable drug delivery systems.
In this area, BD presents an array of solutions for specimen and blood collection and an extensive selection of diagnostic tools, including automated culturing for blood and tuberculosis, molecular testing systems, products for microorganism identification, and drug susceptibility testing. The segment also specializes in liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media products. For cellular analysis, it offers fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, crucial for clinical oncology, immunological research, and transplantation diagnostics or monitoring.
BD's interventional segment covers a wide range of surgical and medical products, including those for hernia and soft tissue repair, biosurgery, and surgical infection prevention. It also offers biological and bioresorbable grafts, peripheral intervention products, and equipment for urology and critical care. These products are designed to improve patient outcomes and support the efficiency of medical procedures.